ResMed Inc. has agreed to sell its MatrixCare healthcare software business to Frazier Healthcare Partners for $490 million in cash, reversing part of a diversification strategy that began when the medical-device company acquired MatrixCare for $750 million in 2018. The transaction is expected to close during the first quarter of Resmed’s fiscal year 2027, subject to regulatory approvals and customary closing conditions.
The divestment will remove a business expected to generate approximately $220 million in fiscal 2026 revenue and $55 million in non-GAAP operating profit. Resmed intends to use the net proceeds partly for an accelerated share-repurchase programme, while retaining flexibility to fund general corporate priorities.
The sale does not represent a complete withdrawal from healthcare software. Resmed will retain Brightree in the United States and MEDIFOX DAN in Germany, both of which are more closely connected to home medical equipment, respiratory care and the company’s broader home-based healthcare strategy. MatrixCare, by contrast, serves more than 15,000 providers across skilled nursing, senior living, life plan communities, home health and hospice care.
Frazier Healthcare Partners plans to operate MatrixCare as a focused post-acute care technology company and invest in product innovation. For Resmed, the transaction simplifies its portfolio but also raises a difficult valuation question: why is a profitable software asset being sold for substantially less than the price paid eight years earlier?
Why has Resmed decided that MatrixCare no longer belongs at the centre of its growth strategy?
Resmed originally acquired MatrixCare to broaden its presence beyond connected sleep and respiratory devices. The company believed that software serving skilled nursing, senior living and other post-acute settings could complement Brightree and create a larger digital ecosystem around care delivered outside hospitals.
That rationale was logical when healthcare providers were rapidly digitising administrative and clinical workflows. MatrixCare brought electronic health records, billing, care-management and operational software into healthcare settings where Resmed had limited direct exposure.
Resmed’s strategic priorities have since become more concentrated. Its current growth narrative is centred on sleep health, breathing health and technology-enabled care delivered in patients’ homes. Connected continuous positive airway pressure devices, masks, ventilation products, patient-engagement applications and software used by home medical equipment providers fit naturally within that ecosystem.
MatrixCare extends further into long-term care institutions, senior living communities and skilled nursing facilities. Those customers remain important parts of healthcare, but the commercial connection to Resmed’s respiratory-device portfolio is less direct.
Selling the business allows management to concentrate capital and organisational attention on areas where hardware, patient data and software can reinforce one another. The logic is not that MatrixCare lacks value. It is that the company may create more value under an owner prepared to treat post-acute care software as its primary investment rather than one component of a diversified medical-technology group.
What exactly is included in the $490 million MatrixCare transaction?
The transaction includes MatrixCare and related software historically sold under the MatrixCare brand. It also covers Healthcare First, Citus and home health and hospice software included within the defined MatrixCare business.
These products support healthcare organisations with electronic records, financial management, care coordination, medication workflows, interoperability and other operational functions. The customer base spans skilled nursing providers, senior living operators, life plan communities, home health agencies and hospice organisations.
Resmed will retain Brightree, which provides software for home medical equipment providers, pharmacies and home infusion organisations. Brightree has a closer commercial relationship with the distribution and management of respiratory equipment, including continuous positive airway pressure devices and supplies.
MEDIFOX DAN will also remain with Resmed. The German software business supports outpatient and inpatient care providers and contributes to Resmed’s European connected-care presence.
The separation therefore follows business-model boundaries rather than simply disposing of all non-device software. Resmed is retaining platforms that management believes remain strategically linked to home-based care while selling a group of products with deeper exposure to long-term care and institutional post-acute markets.
Until closing, MatrixCare will continue operating within Resmed without planned changes to customer service or support. The companies expect to establish transition-services agreements covering systems, processes, tools and daily operations after completion.
Those arrangements are important because MatrixCare has been integrated into Resmed for years. Functions such as finance, technology infrastructure, human resources and procurement may need to be separated or temporarily shared while Frazier Healthcare Partners establishes an independent operating model.
Did Resmed destroy value by buying MatrixCare for $750 million and selling it for $490 million?
The headline comparison is uncomfortable. Resmed paid $750 million in cash for MatrixCare in November 2018 and is now selling the business for $490 million, a nominal decline of $260 million, or nearly 35%.
The business itself has grown. At the time of the acquisition, MatrixCare was expected to produce approximately $122 million in annual revenue and $30 million in adjusted earnings before interest, taxes, depreciation and amortisation. Preliminary fiscal 2026 figures indicate about $220 million in revenue and $55 million in non-GAAP operating profit.
Revenue has therefore increased by roughly 80% from the level disclosed around the acquisition. The expected operating contribution has also grown substantially, although the 2018 and 2026 profit measures are not directly identical.
The valuation multiple has compressed sharply. Resmed originally paid more than six times expected annual revenue and about 25 times projected adjusted earnings before interest, taxes, depreciation and amortisation. Frazier Healthcare Partners is paying approximately 2.2 times current revenue and about 8.9 times non-GAAP operating profit.
That difference reflects more than operational performance. Software valuations were considerably stronger when investors were willing to pay high multiples for recurring revenue and digital healthcare expansion. Financing costs have since risen, growth expectations have moderated and artificial intelligence has introduced both opportunities and disruption risks across established software categories.
Resmed may also be accepting a lower multiple because MatrixCare is no longer regarded as a strategic asset. A company seeking portfolio simplicity may prioritise certainty, speed and capital redeployment rather than holding out indefinitely for a valuation matching its historical purchase price.
The transaction should not automatically be described as a complete financial failure. MatrixCare generated revenue, profit and cash during Resmed’s ownership, and those cumulative contributions are not reflected in the simple comparison between acquisition and sale prices.
Even so, the sale demonstrates that the original strategic premium was not recovered at exit. Resmed is effectively acknowledging that the business is worth less inside its current portfolio than management believed it would be when the acquisition was completed.
Why is Frazier Healthcare Partners willing to buy a business Resmed considers less strategic?
Frazier Healthcare Partners is approaching MatrixCare from a different position. The private equity firm does not need the software company to generate synergies with sleep-apnoea devices or respiratory equipment. It can evaluate the asset as a standalone platform serving post-acute and long-term care providers.
The firm has spent several years studying healthcare technology used in skilled nursing, senior living, home health and hospice care. These markets face persistent operational pressure from staff shortages, reimbursement complexity, regulatory requirements and the need to coordinate patients across different settings.
Software capable of improving billing, documentation, scheduling, medication management and workforce productivity can remain valuable even when the market is growing more slowly than other healthcare technology categories.
Private ownership could also allow MatrixCare to pursue investment and restructuring without being measured against the faster-growing portions of Resmed’s portfolio every quarter. Frazier Healthcare Partners has indicated that it plans to invest aggressively in product innovation.
That investment may include modernising software architecture, adding automation, improving interoperability and embedding artificial intelligence into administrative and clinical workflows. MatrixCare’s established customer base gives Frazier Healthcare Partners a distribution platform through which new products can be introduced.
The buyer may also pursue acquisitions. Post-acute care technology remains fragmented, with specialist vendors serving different settings and functions. MatrixCare could become a platform for consolidating complementary software companies.
The private equity model will still require disciplined returns. Frazier Healthcare Partners must grow revenue, protect customer retention and improve profitability sufficiently to justify the purchase and any additional investment.
Could artificial intelligence explain why MatrixCare was sold at a lower-than-expected multiple?
Artificial intelligence creates a mixed outlook for established healthcare software businesses. It can make platforms more useful by automating documentation, coding, scheduling, clinical summaries and administrative work. At the same time, it can lower barriers for newer competitors and reduce the value of older software functions that were previously difficult to replicate.
MatrixCare serves organisations operating under severe staffing and cost pressure. Artificial intelligence tools that reduce documentation time or improve revenue-cycle performance could provide a strong commercial opportunity.
The risk is that customers may expect these capabilities to be included without substantial price increases. MatrixCare could be forced to spend heavily on product development merely to defend existing revenue rather than create a new high-margin growth engine.
New entrants may also build cloud-native products around artificial intelligence without carrying the technical debt associated with older healthcare software systems. Legacy platforms can possess deep functionality and regulatory knowledge, but modernising them across many customer configurations can be expensive.
The sale valuation suggests that buyers were unwilling to apply premium software multiples to MatrixCare’s current earnings. One interpretation is that the business is mature and requires significant investment to accelerate. Another is that the market has become more cautious about how artificial intelligence will reshape electronic health records and administrative software.
Frazier Healthcare Partners appears willing to accept that risk because it can focus directly on the transformation. Resmed may prefer to invest in artificial intelligence where it strengthens sleep diagnostics, treatment adherence, connected devices and respiratory care.
How much will the transaction change Resmed’s financial profile?
MatrixCare’s estimated $220 million of fiscal 2026 revenue represents a relatively small portion of Resmed’s overall business. The company generated approximately $1.4 billion of revenue in the third quarter alone, supported by continuing growth in sleep and respiratory devices, masks and software.
The divestment will nevertheless remove about $55 million of annual non-GAAP operating profit. Resmed will need to eliminate stranded corporate costs to prevent the sale from creating a disproportionate drag on earnings.
Transition-services agreements are expected to offset most stranded costs during the first year after closing. Resmed then plans to reduce or eliminate remaining expenses over time.
The company continues to expect its remaining Residential Care Software operations to deliver high-single-digit percentage revenue growth in fiscal 2027, accompanied by operating leverage. That expectation will be closely examined after MatrixCare is removed because the retained segment will have a different geographic and customer mix.
Brightree and MEDIFOX DAN will become the core of the remaining software portfolio. Their performance will indicate whether Resmed can create a tighter connection between software, medical equipment providers and patients using respiratory products at home.
The accelerated share-repurchase programme may soften the near-term earnings effect by reducing the number of shares outstanding. At a Resmed share price near $204, deploying the full $490 million purchase price could theoretically retire roughly 2.4 million shares before taxes, fees and other uses of proceeds. The actual programme will be based on net proceeds and terms that have not yet been disclosed.
Why is Resmed returning capital instead of using all the proceeds for acquisitions?
Resmed is generating substantial operating cash flow and entered the transaction from a position of financial strength. During the third quarter of fiscal 2026, the company produced $554 million of operating cash flow, paid $87 million in dividends and repurchased approximately $175 million of shares.
Returning additional capital signals that management does not need the MatrixCare proceeds to stabilise the balance sheet. It also suggests that Resmed views its own shares as an attractive use of capital after a significant decline from their 52-week high.
Share repurchases can improve earnings per share when the company buys stock at a reasonable valuation and the underlying business continues to grow. They are less valuable when used merely to offset dilution or distract from slowing operations.
Resmed may still use part of the proceeds for corporate purposes, including investment and acquisitions. The company recently completed its acquisition of Noctrix Health, adding a wearable neuromodulation device for restless legs syndrome.
Noctrix is expected to contribute about $30 million of fiscal 2027 revenue while reducing non-GAAP diluted earnings per share by approximately $0.20 during the investment phase. That profile demonstrates Resmed’s willingness to trade near-term earnings for medical technologies that fit its sleep-health strategy more directly.
The contrast is revealing. Resmed is selling a profitable but strategically peripheral software company and investing in a device platform that expands its core clinical market.
What does the MatrixCare sale mean for customers and employees?
The immediate message is continuity. MatrixCare will remain part of Resmed until the transaction closes, and the company has said there will be no change to customer support during that period.
After completion, customers will be dealing with a newly independent business owned by a healthcare-focused private equity firm. The transition may bring increased product investment, but it can also create uncertainty around pricing, staffing, product priorities and long-term platform consolidation.
Frazier Healthcare Partners has an incentive to retain MatrixCare’s customer relationships because recurring software revenue is central to the business’s value. Disruption during the ownership change would weaken the economics of the acquisition.
Employees may gain from working within a company where post-acute software is the central business rather than one division among medical devices, respiratory care and other software products. Dedicated ownership could create clearer investment priorities and faster decision-making.
Private equity ownership can also lead to cost controls and operational restructuring. Neither party has announced layoffs or major organisational changes, so assumptions about workforce reductions would be premature.
The transition-services period will be an early test. Smooth separation of technology, administrative systems and support functions will determine whether customers experience the deal as an ownership change or an operational disruption.
Why did Resmed shares fall sharply after the MatrixCare announcement?
Resmed shares listed on the New York Stock Exchange closed at $205.84 on July 8, falling 6.3% during the first full trading session after the sale announcement. The stock recovered 1.3% on July 9 before declining another 2.2% to $203.87 on July 10.
The five-session movement left the shares approximately 2.7% below their July 2 close. Over the month from June 10 to July 10, however, the stock remained around 5.3% higher.
Resmed was trading approximately 30.6% below its 52-week high of $293.81 and about 13.1% above its 52-week low of $180.27. The company’s market capitalisation remained close to $29.7 billion.
The negative reaction indicates that investors were not entirely convinced by the transaction economics. The sale price came below the original purchase value and implied a lower earnings multiple than some analysts expected for a recurring-revenue software asset.
Investors may also be calculating the earnings lost from MatrixCare against the benefit of share repurchases. A $55 million annual operating-profit contribution is meaningful, and the proceeds must be deployed effectively for the transaction to improve long-term shareholder value.
The more constructive interpretation is that Resmed has simplified its investment case. The company will have greater exposure to sleep devices, masks, connected care and respiratory technologies, where it holds stronger competitive positions and may be able to sustain higher growth.
Market sentiment therefore appears cautious rather than dismissive. The strategic logic is understandable, but investors want evidence that the proceeds and management attention can generate returns superior to those MatrixCare would have produced if retained.
What should investors watch before the MatrixCare transaction closes?
The first issue is regulatory approval and confirmation of the closing timetable. Resmed expects completion during the first quarter of fiscal 2027, but the precise date has not been announced.
Details of the accelerated share-repurchase programme will determine how much capital is returned and how quickly the transaction begins affecting the share count. Investors will also watch whether Resmed retains funds for additional strategic investments.
The company’s fiscal 2027 outlook, expected with its fourth-quarter results on August 6, should clarify the effects on revenue, operating profit and earnings per share. Guidance will need to distinguish the loss of MatrixCare from the contribution and investment burden associated with Noctrix Health.
Performance from Brightree and MEDIFOX DAN will become more important after the sale. High-single-digit growth in the retained software portfolio would support management’s argument that Resmed is keeping the assets most closely connected to its home-care strategy.
Frazier Healthcare Partners’ plans for MatrixCare will also reveal whether the buyer views the platform primarily as a stable cash-generating asset or a foundation for renewed product development and acquisitions.
Resmed is accepting a lower headline price than it paid in 2018, but the strategic calculation extends beyond that comparison. Management is exchanging a mature long-term care software business for cash, share repurchases and greater concentration in markets where devices, patient engagement and connected data operate as one system.
The transaction will look disciplined only if the remaining company grows faster and produces better returns. Until that evidence arrives, the MatrixCare sale will remain both a portfolio simplification and a reminder that healthcare software acquisitions bought at premium valuations do not always deliver premium exits.
